ArticleEpidemiology and infection2020
The role of haematological parameters in patients with COVID-19 and influenza virus infection.
Article in Epidemiology and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Differences in clinical characteristics between coronavirus disease 2019 (COVID-19) and influenza: a systematic review and meta-analysis.NPJ primary care respiratory medicine · 2025Pooled it
- Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis.Clinical reviews in allergy & immunology · 2023Pooled it
- Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- The diagnostic value of decreased levels of inflammatory markers for the state of hepatitis C virus (HCV) infection.PloS one · 2025Article
- The role of hematological parameters in asymptomatic and non-severe cases of Omicron variant infection.Virology journal · 2024Article
- Clinical characteristics and prognostic marker for hospitalization in children with influenza infection in an emergency setting.BMC pediatrics · 2024Article
- Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Review
- Blood Count and Renal Functionality Assessments in the Emergency Section Disclose Morbidity and Mortality in Omicron COVID-19 Patients: A Retrospective Study.Clinics and practice · 2024Article
- Can Haematological Parameters Discriminate COVID-19 from Influenza?Journal of clinical medicine · 2023Article
- Immune responses in mildly versus critically ill COVID-19 patients.Frontiers in immunology · 2023Review
- Hematocytological Clues of Peripheral Blood in Different Clinical Presentations of COVID-19.Iranian journal of pathology · 2023Article
- Associated Biochemical and Hematological Markers in COVID-19 Severity Prediction.Advances in medicine · 2023Article
- Clinical manifestations of COVID-19 in patients with asthma, hypertension, and diabetes mellitus.Journal of medicine and life · 2022Article
- Article
- Influenza is more severe than our newest enemy (COVID-19) in hospitalized children: Experience from a tertiary center.Journal of medical virology · 2022Article
- Review
- Platelets in Viral Infections - Brave Soldiers or Trojan Horses.Frontiers in immunology · 2022Review
- Comparative analysis of neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio with respect to outcomes of in-hospital coronavirus disease 2019 patients: A retrospective study.Frontiers in medicine · 2022Article
- Role of Basophils in a Broad Spectrum of Disorders.Frontiers in immunology · 2022Review
- Changes of Routine Hematological Parameters in COVID-19 Patients: Correlation with Imaging Findings, RT-PCR and Outcome.Iranian journal of pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2, the causative agent of coronavirus disease 19 (COVID-19), was identified in Wuhan, China. Since then, the novel coronavirus started to be compared to influenza. The haematological parameters and inflammatory indexes are associated with severe illness in COVID-19 patients. In this study, the laboratory data of 120 COVID-19 patients, 100 influenza patients and 61 healthy controls were evaluated. Lower lymphocytes, eosinophils, basophils, platelets and higher delta neutrophil index (DNI), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were found in COVID-19 and influenza groups compared to healthy controls. The eosinophils, lymphocytes and PLR made the highest contribution to differentiate COVID-19 patients from healthy controls (area under the curves (AUCs): 0.819, 0.817 and 0.716, respectively; P-value is <0.0001 for all). The NLR, the optimal cut-off value was 3.58, which resulted in a sensitivity of 30.8 and a specificity of 100 (AUC: 0.677, P < 0.0001). Higher leucocytes, neutrophils, DNI, NLR, PLR and lower lymphocytes, red blood cells, haemoglobin, haematocrit levels were found in severe patients at the end of treatment. Nonsevere patients showed an upward trend for lymphocytes, eosinophils and platelets, and a downward trend for neutrophils, DNI, NLR and PLR. However, there was an increasing trend for eosinophils, platelets and PLR in severe patients. In conclusion, NLR and PLR can be used as biomarkers to distinguish COVID-19 patients from healthy people and to predict the severity of COVID-19. The increasing value of PLR during follow-up may be more useful compared to NLR to predict the disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.